阿仑单抗治疗中促甲状腺激素受体抗体的纵向特征:TRAb可能早于甲状腺功能障碍多年出现
该研究对45例接受阿仑单抗治疗的多发性硬化患者进行长达九年的回顾性纵向分析,其中31例发生甲状腺功能障碍。采用自制流式细胞术和荧光素酶生物分析法检测TRAb,发现TRAb可在甲状腺功能改变前数年出现,且基线ihTRAb阳性强烈预测后续甲状腺功能障碍。
要点
- 阿仑单抗治疗患者中,ihTRAb可在甲状腺功能障碍发生前中位1.2年检出。
- 基线ihTRAb阳性预测后续甲状腺功能障碍,联合TPOAb可提高预测能力。
- 常规自动化TRAb检测可能漏检早期自身免疫反应,需高灵敏度方法。
核心结论
- TRAb可在阿仑单抗相关甲状腺功能障碍发生前多年被检出,提示自身免疫过程早于临床发病。
研究设计与样本
- 纵向回顾性分析,纳入45例接受阿仑单抗治疗的多发性硬化患者,其中31例发生甲状腺功能障碍,14例保持甲状腺功能正常至少五年。
主要发现
- 阿仑单抗治疗前,ihTRAb在甲状腺功能障碍组阳性率为5/16(31.2%),而甲状腺功能正常组为0/14(0%)(p=0.017)。
- ihTRAb在9/28(32.1%)的甲状腺功能障碍患者中可检出,且早于甲状腺功能障碍发生的中位时间为1.2年(范围28天至7.3年)。
- 基线ihTRAb联合TPOAb检测预测后续20%的甲状腺功能亢进症和83%的甲状腺功能减退症。
临床怎么用
- 对接受阿仑单抗治疗的多发性硬化患者,可考虑使用高灵敏度TRAb检测进行基线筛查和纵向监测。
- 联合检测TPOAb和ihTRAb有助于识别高危患者,为早期干预提供依据。
局限性
- 回顾性研究,样本量较小(45例),且使用自制检测方法,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thyroid autoimmunity, especially Graves' disease or hypothyroidism with positive autoantibodies (TRAb) to the thyrotropin receptor (TSHR), occurs in 30-40% of patients with relapsing multiple sclerosis following treatment with alemtuzumab (ALTZ). ALTZ therapy therefore provides a unique opportunity to study the evolution of TRAb prior to clinical presentation. TRAb can stimulate (TSAb), block (TBAb), or not affect ("neutral") the TSHR function, causing hyperthyroidism, hypothyroidism, or euthyroidism, respectively. METHODS: A longitudinal retrospective analysis was conducted of TRAb bioactivity over a period of nine years in 45 multiple sclerosis patients receiving ALTZ using available stored serum. Of these 45 patients, 31 developed thyroid dysfunction (TD) and 14 remained euthyroid despite being followed for a minimum of five years (NO-TD). The presence of TRAb was evaluated at standardized time points: (i) before ALTZ, (ii) latest time available following ALTZ and before TD onset, and (iii) following ALTZ during/after TD onset. Serum TRAb were detected by published in-house assays (ihTRAb): flow cytometry detecting any TSHR-binding TRAb, and luciferase bioassays detecting TSAb/TBAb bioactivity. Purified immunoglobulin G was used to verify TSAb/TBAb in selected hypothyroid cases. Standard clinical automated measurements of TRAb, antithyroid peroxidase autoantibodies (TPOAb), thyrotropin, free thyroxine, and free triiodothyronine were also collected. RESULTS: Before ALTZ, combined ihTRAb (positive with flow cytometry and/or luciferase bioassay) but not automated TRAb were present in 5/16 (31.2%) TD versus 0/14 (0%) NO-TD (p = 0.017). Detectable ihTRAb preceded TD development in 9/28 (32.1%) and by a median of 1.2 years (range 28 days-7.3 years). Combination testing of ihTRAb and TPOAb at baseline predicted 20% of subsequent cases of hyperthyroidism and 83% of hypothyroidism. CONCLUSIONS: Evidence is presented that TRAb measured with custom-made assays can be detected prior to any change in thyroid function in up to a third of cases of ALTZ-related TD. Furthermore, the presence of ihTRAb prior to ALTZ treatment was strongly predictive of subsequent TD. The findings suggest that a period of affinity maturation of TRAb may precede clinical disease onset in some cases. Combined testing of TPOAb and ihTRAb may increase the ability to predict those who will develop TD following ALTZ.
引用
- Muller I, Willis M, Healy S, et al. Longitudinal Characterization of Autoantibodies to the Thyrotropin Receptor (TRAb) During Alemtuzumab Therapy: Evidence that TRAb May Precede Thyroid Dysfunction by Many Years. Thyroid. 2018. PMID: 30351224. doi:10.1089/thy.2018.0232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。